X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.clinicaltrialsarena.com/news/onconova-patient-cancer-combo/
https://www.globenewswire.com/news-release/2023/05/11/2666685/0/en/Onconova-Therapeutics-Doses-First-Patient-in-Phase-1-2a-Trial-of-Narazaciclib-Combined-with-Letrozole-in-Endometrial-Cancer.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215975
https://www.globenewswire.com/news-release/2022/11/14/2555467/0/en/Onconova-Therapeutics-Announces-Plans-for-a-Phase-1-2a-Trial-of-Narazaciclib-Combined-with-Letrozole-in-Endometrial-Cancer-Reports-Third-Quarter-2022-Financial-Results-and-Provides.html
https://www.fiercepharma.com/pharma/asco-pfizers-ibrance-fails-extend-lives-newly-diagnosed-breast-cancer-will-doctors-switch
https://www.europeanpharmaceuticalreview.com/news/169184/kisqali-longest-median-os-breast-cancer/
https://www.globenewswire.com/news-release/2021/09/19/2299389/0/en/Novartis-presents-new-Kisqali-data-showing-longest-median-overall-survival-ever-reported-in-HR-HER2-advanced-breast-cancer.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205869
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
http://www.pmlive.com/pharma_news/lilly_adds_to_data_backing_breast_cancer_candidate_abemaciclib_1194792
http://www.prnewswire.com/news-releases/novartis-receives-fda-approval-for-first-of-its-kind-kisqali-femara-co-pack-for-initial-treatment-of-hrher2--advanced-or-metastatic-breast-cancer-300453393.html
http://www.nasdaq.com/article/pfizer-pfe-nimenrix-vaccines-label-expanded-in-the-eu-cm724871
http://www.nasdaq.com/article/novartis-announces-addl-analyses-from-phase-iii-monaleesa2-study-20161209-00289
http://www.pmlive.com/pharma_news/pfizers_first-in-class_breast_cancer_therapy_wins_eu_licensing_1176260?
http://www.fool.com/investing/2016/11/03/novartis-takes-aim-at-pfizer.aspx?
http://www.prnewswire.com/news-releases/novartis-breakthrough-therapy-lee011-ribociclib-plus-letrozole-demonstrates-superior-progression-free-survival-as-first-line-treatment-for-hrher2--advanced-breast-cancer-compared-to-a-standard-of-care-300341417.html
https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf
http://www.forbes.com/sites/elaineschattner/2016/06/08/major-report-touts-benefits-of-prolonged-femara-use-after-breast-cancer-im-not-convinced/#585b487a34ff
http://www.fiercepharma.com/marketing/mano-a-mano-between-pfizer-s-ibrance-and-novartis-lee011-nears-early-phiii-wrap-up
http://www.pharmatimes.com/Article/16-04-20/Data_back_efficacy_of_Pfizer_s_breast_cancer_drug_Ibrance.aspx
http://www.biospectrumasia.com/biospectrum/news/221623/daiichi-sankyo-s-subsidiary-launches-generic-drugs
http://indianexpress.com/article/india/india-others/12-cancer-drugs-may-come-under-price-control/
http://www.marketwatch.com/story/pfizer-announces-palbociclib-paloma-1-data-published-in-the-lancet-oncology-2014-12-15
Market Place
Share 
